CADL
NASDAQ
US
Candel Therapeutics, Inc. - Common Stock
$5,00
▲ +$0,02
(+0,40%)
Vol. 901K
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$310.2M
ROE
-29,2%
Margine
-15156,5%
D/E
6,49
Beta
-0,87
52W
$4–$14
Consenso Wall Street
14 analisti · Apr 20264
Acquisto forte
8
Compra
2
Mantieni
0
Vendi
0
Vendita forte
85,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
GNLX
Genelux Corp
$165.9M
SGMO
Sangamo Therapeutics Inc
$141.3M
BMEA
Biomea Fusion Inc
$87.7M
KPTI
Karyopharm Therapeutics Inc
$125.5M
CRDF
Cardiff Oncology Inc
$189.3M
ALDX
Aldeyra Therapeutics Inc
$99.9M
SPRB
Spruce Biosciences, Inc
$93.2M
COYA
Coya Therapeutics Inc
$121.4M
QTTB
Q32 Bio Inc
$40.9M
Utili
Tasso di battuta: 40,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-0,34
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,34 | — | — |
| Dic 2025 | $-0,25 | $-0,54 | $-0,29 |
| Set 2025 | $-0,19 | $-0,21 | $-0,02 |
| Giu 2025 | $-0,17 | $-0,09 | +$0,08 |
Ricavi e utili trimestrali
| Trimestre | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — |
| Utile netto | -$14.1M | $7.4M | -$4.8M | -$11.3M | -$29.5M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -14.9% | -14.9% | -14.9% | -14.9% | -14.9% | -29.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -15156.5% | -15156.5% | -15156.5% | -15156.5% | -15156.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 8.47 | 8.47 | 8.47 | 8.47 | 8.47 | 6.49 |
| Current Ratio | 7.04 | 7.04 | 7.04 | 7.04 | 7.04 | 8.25 |
Rapporti chiave
ROA (TTM)
-22,6%
P/S (TTM)
2501,41
P/B
5,5
EPS (TTM)
$-0,56
CF/Share
$-1,07
52W High
$13,68
52W Low
$4,25
$4,25
Intervallo 52 settimane
$13,68
Salute finanziaria
Flusso di cassa libero
-$11.0M
Debito netto
-$70.7M
Liquidità
$119.7M
Debito totale
$49.0M
Aggiornato al Dic 31, 2025
Як CADL виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CADL vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
2501,4
▲
19366%
sopra
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
5,5
▲
124%
sopra
peer
(2,5)
vs Peer
vs Settore
Sopravvalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CADL vs аналоги Biotechnology
ROE
-29,2%
▲
57%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Top livello
Net margin
-15156,5%
▼
5186%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-22,6%
▲
52%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Top livello
Фінансове здоровʼя CADL vs аналоги Biotechnology
D/E ratio
6,5
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
8,3
▲
86%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
-0,9
▼
190%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CADL
CADL
Mediana peer
Industria
CADL прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CADL vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
MANNING PAUL B.
Director · Feb 23
550458 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 24,13%FMR, LLC
11,24%
$39.6M
Blackrock Inc.
3,91%
$13.8M
Acorn Capital Advisors, LLC…
3,52%
$12.4M
Vanguard Group Inc
3,15%
$11.1M
Portolan Capital Management…
2,31%
$8.2M
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora